Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

HIV: Update Bulletin [December 2014]

Product Code:
596200331
Release Date:
December 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in HIV: Gilead’s tenofovir alafenamide (TAF)-based Stribild, TAF on the future competitiveness of TAF-containing regimens, Janssen’s darunavir-based, single-pill combination.

Highlights from this event update bulletin

  • What will be the most important factor in the uptake of Gilead’s TAF-based Stribild?
  • How will the inclusion of TAF in Stribild impact its competitiveness with ViiV Healthcare’s Triumeq?
  • What is the outlook for Janssen’s protease inhibitor-based, once-daily, single-pill regimen?
  • How will the results of the NA-ACCORD study looking at the cardiovascular risk of abacavir impact the outlook for Gilead’s TAF-based Stribild and ViiV Healthcare’s Triumeq?
  • How are darunavir and doluetegravir viewed in terms of their respective barriers to resistance and what are the implications in practice?
  • What is the clinical significance of tenofovir alafenamide (TAF)’s improvements on renal and bone parameters and will they translate to a commercial advantage?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved